Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-305: Tarlatamab + Durvalumab vs Durvalumab in ES-SCLC Maintenance
jRCT2051240045Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Tarlatamab + Durvalumab with Durvalumab alone (2 arms). Primary endpoint: Overall survival (OS). Started Jun 2024; status: active, not recruiting.
02
Drugs
tarlatamabdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2051240045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240045.